Table of Content

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Why do companies partner preclinical stage compounds?

2.1. Introduction
2.2. The role of preclinical stage partnering
2.2.1. In-licensing at preclinical stage
2.2.2. Out-licensing at preclinical stage
2.3. Difference between discovery, preclinical and clinical stage deals
2.4. Reasons for entering into preclinical stage partnering deals
2.4.1. Licensors reasons for entering preclinical stage deals
2.4.2. Licensees reasons for entering preclinical stage deals
2.5. The future of preclinical stage partnering deals

Chapter 3 – Preclinical stage deal strategies and structure

3.1. Introduction
3.2. At what stage do companies partner?
3.2.1. Partnering early in pharmaceutical / biotech
3.2.1.1. Discovery and preclinical stage partnering case studies
3.2.1.1.a. Case study 1
3.2.1.1.b. Case study 2
3.2.1.1.c. Case study 3
3.2.1.1.d. Case study 4
3.2.2. Partnering later in pharmaceutical/biotech
3.2.2.1. Clinical stage partnering case studies
3.2.2.1.a. Case study 5
3.2.2.1.b. Case study 6
3.2.2.1.c. Case study 7
3.2.2.1.d. Case study: 8
3.3. Early and later stage partnering – a risk/cost comparison
3.4. What do companies spend on preclinical stage partnering?
3.5. Pure versus multi-component partnering deals
3.6. Pure licensing agreement structure
3.6.1. Example pure preclinical stage licensing agreements
3.6.1.a. Case study 9
3.6.1.b. Case study 10
3.7. Multicomponent preclinical stage partnering agreements
3.7.1. Example multicomponent preclinical stage clauses
3.7.1.a. Case study: 11
3.7.1.b. Case study 12

Chapter 4 – Preclinical stage partnering payment strategies

4.1. Introduction
4.2. Preclinical stage payment strategies
4.3. Payment options
4.3.1. Headline values
4.3.2. Upfront payments
4.3.2.1. Conditionality of upfront payments
4.3.3. Loans
4.3.4. Convertible loans
4.3.5. Equity
4.3.6. R&D funding
4.3.7. Licensing fees
4.3.8. Milestone payments
4.3.9. Royalty payments
4.3.9.1. Issues affecting royalty rates
4.3.9.2. Royalties on combination products
4.3.9.2.a. Case study 13
4.3.9.3. Guaranteed minimum/maximum annual payments
4.3.9.4. Royalty stacking
4.3.9.5. Royalties and supply/purchase contracts
4.3.10. Quids
4.3.11. Option payments

Chapter 5 – Trends in preclinical stage deal making

5.1. Introduction
5.2. Preclinical stage partnering over the years
5.2.1. Attributes of preclinical deals
5.3. Preclinical stage partnering by deal type
5.4. Preclinical stage partnering by disease type
5.5. Partnering by preclinical stage technology type
5.6. Preclinical stage partnering by most active company since 2016

Chapter 6 – Payment terms for preclinical stage partnering

6.1. Introduction
6.2. Guidelines for preclinical stage payment terms
6.2.1. Upfront payments
6.2.2. Milestone payments
6.2.3. Royalty payments
6.3. Preclinical stage payment terms – deal data analysis
6.3.1. Public data
6.3.2. Survey data
6.4. Payment terms analysis
6.4.1. Preclinical stage headline values
6.4.2. Preclinical stage deal upfront payments
6.4.3. Preclinical stage deal milestone payments
6.4.4. Preclinical stage royalty rates

Chapter 7 – Leading preclinical stage deals

7.1. Introduction
7.2. Top preclinical stage deals by value

Chapter 8 – Top 25 most active preclinical stage dealmakers

8.1. Introduction
8.2. Top 25 most active preclinical stage dealmakers

Chapter 9 – Preclinical stage partnering contracts directory

9.1. Introduction
9.2. Preclinical stage deals with contracts 2016 to 2023

Chapter 10 – Preclinical stage deal making by development stage

10.1. Introduction
10.2. Deals by preclinical stage

Appendices

Appendix 1 – Preclinical stage dealmaking by companies A-Z
Appendix 2 – Preclinical stage dealmaking by industry sector
Appendix 3 – Preclinical stage dealmaking by stage of development
Appendix 4 – Preclinical stage dealmaking by therapy area
Appendix 5 – Preclinical stage dealmaking by technology type

About Wildwood Ventures

Current Partnering
Current Agreements
Recent titles from Current Partnering

Table of figures

Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking
Figure 2: Components of the pure licensing deal structure
Figure 3: Payment options for preclinical stage partnering deals
Figure 4: Issues affecting royalty rates
Figure 5: Preclinical stage partnering frequency 2016 - 2023
Figure 6: Preclinical stage partnering by deal type since 2016
Figure 7: Preclinical stage partnering by disease type since 2016
Figure 8: Preclinical stage partnering by technology type since 2016
Figure 9: Top 25 most active preclinical stage dealmakers, 2016 to 2023
Figure 10: Review of upfront payments for preclinical stage deals
Figure 11: Review of milestone payments for preclinical stage deals
Figure 12: Review of royalty payments for preclinical stage deals
Figure 13: Preclinical stage deals with a headline value
Figure 14: Preclinical stage deals with an upfront value
Figure 15: Preclinical stage deals with a milestone value
Figure 16: Preclinical stage deals with a royalty rate value
Figure 17: Top preclinical stage deals by value since 2016
Figure 18: Most active preclinical stage dealmakers 2016 to 2023